The composition and volume of tear fluid lining the ocular surface are governed by the rates of lacrimal gland secretion, tear film evaporation, nasolacrimal drainage, and epithelial ion and water transport. Tear fluid hyperosmolality and reduced volume are key drivers of dry eye disease (DED) pathogenesis. We constructed a mathematical model to compute the composition and volume of tear fluid and epithelial cell compartments, with transport parameters specified for the mouse eye based on published data and in vivo measurements of ocular surface potential differences. The model accounted for transcellular and paracellular transport across the epithelia under open-circuit conditions utilizing flux equations for individual transport mechanisms, with mass balance constraints on solute and water content in cytoplasm and tear fluid. Model computations revealed a rough orthogonality between the determinants of tear fluid volume and osmolality in which lacrimal secretion and nasolacrimal drainage primarily regulate tear fluid volume, whereas evaporation and transepithelial osmosis primarily regulate tear fluid osmolality. Under DED conditions established by reduced lacrimal secretion and increased evaporation, the model predicted the efficacy of currently available DED therapies, including punctal plugs, humidification goggles, lacrimal gland stimulation, and artificial tear eye drops. The model also predicted the limited efficacy of anti-absorptive and pro-secretory drugs targeting epithelial ion transporters and the high efficacy of targeting epithelial water permeability or paracellular ion permeability. The modeling herein provided quantitative predictions to prioritize drug targets for DED to drive the development of novel therapies.
Model of ocular surface ion and water transport predicts efficacy of dry eye therapeutics
Disclosures: M.H. Levin reported personal fees from Vanda Pharmaceuticals outside the submitted work; in addition, M.H. Levin had a patent to 4836-577PO1US, “CFTR regulators and methods of use” 4836-578PO1US, “CFTR regulators and methods of use therefor” 4836-579PO1US, and “CFTR regulators and methods of use thereof” US Patents (filed 12/2016 by UCSF, issued 3/31/2020), with royalties paid to Vanda Pharmaceuticals and a patent to “Apparatus, Systems, and Methods of Use for Ocular Surface Potential Difference Measurement” US Patents (SF2019-237-2-US, 17/469,282, filed by UCSF 09/2021) issued. N.D. Pasricha reported personal fees from Vanda Pharmaceuticals outside the submitted work; in addition, N.D. Pasricha had a patent to apparatus, systems, and methods of use for ocular surface potential difference measurement issued to University of California San Francisco. A.S. Verkman is a named inventor on patent applications on CFTR activators for treatment of dry eye disease and OSPD measurements in humans. Patent rights are owned by the University of California. No other disclosures were reported.
- Award Id(s): EY036139,P30EY002162,EY033859,EY013574
- Award Id(s): DK126070,DK072517
Varun Verma, Ethan S. Lindgren, Marc H. Levin, Onur Cil, Lukmanee Tradtrantip, Rongshan Yan, Neel D. Pasricha, Alan S. Verkman; Model of ocular surface ion and water transport predicts efficacy of dry eye therapeutics. J Gen Physiol 6 July 2026; 158 (4): e202513958. doi: https://doi.org/10.1085/jgp.202513958
Download citation file:
Sign in
Suggested Content
Email alerts
Advertisement
